These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 34029488)

  • 1. Absence of Humoral Response After Two-Dose SARS-CoV-2 Messenger RNA Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: A Case Series.
    Connolly CM; Boyarsky BJ; Ruddy JA; Werbel WA; Christopher-Stine L; Garonzik-Wang JM; Segev DL; Paik JJ
    Ann Intern Med; 2021 Sep; 174(9):1332-1334. PubMed ID: 34029488
    [No Abstract]   [Full Text] [Related]  

  • 2. Temporary hold of mycophenolate augments humoral response to SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases: a case series.
    Connolly CM; Chiang TP; Boyarsky BJ; Ruddy JA; Teles M; Alejo JL; Massie A; Werbel WA; Shah AA; Christopher-Stine L; Garonzik-Wang J; Segev DL; Paik JJ
    Ann Rheum Dis; 2022 Feb; 81(2):293-295. PubMed ID: 34556484
    [No Abstract]   [Full Text] [Related]  

  • 3. SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response.
    Bonelli MM; Mrak D; Perkmann T; Haslacher H; Aletaha D
    Ann Rheum Dis; 2021 Oct; 80(10):1355-1356. PubMed ID: 33958323
    [No Abstract]   [Full Text] [Related]  

  • 4. Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases.
    Spiera R; Jinich S; Jannat-Khah D
    Ann Rheum Dis; 2021 Oct; 80(10):1357-1359. PubMed ID: 33975857
    [No Abstract]   [Full Text] [Related]  

  • 5. Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2.
    Braun-Moscovici Y; Kaplan M; Braun M; Markovits D; Giryes S; Toledano K; Tavor Y; Dolnikov K; Balbir-Gurman A
    Ann Rheum Dis; 2021 Oct; 80(10):1317-1321. PubMed ID: 34144967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases.
    Ruddy JA; Connolly CM; Boyarsky BJ; Werbel WA; Christopher-Stine L; Garonzik-Wang J; Segev DL; Paik JJ
    Ann Rheum Dis; 2021 Oct; 80(10):1351-1352. PubMed ID: 34031032
    [No Abstract]   [Full Text] [Related]  

  • 7. Serum antibody response in patients with philadelphia-chromosome positive or negative myeloproliferative neoplasms following vaccination with SARS-CoV-2 spike protein messenger RNA (mRNA) vaccines.
    Kozak KE; Ouyang L; Derkach A; Sherman A; McCall SJ; Famulare C; Chervin J; Daley RJ; Morjaria S; Mauro MJ; Rampal RK
    Leukemia; 2021 Dec; 35(12):3578-3580. PubMed ID: 34741117
    [No Abstract]   [Full Text] [Related]  

  • 8. Time course of antibody concentrations against the spike protein of SARS-CoV-2 among healthy hospital workers up to 200 days after their first COVID-19 vaccination.
    Mueller T
    J Clin Lab Anal; 2022 Jan; 36(1):e24175. PubMed ID: 34910338
    [No Abstract]   [Full Text] [Related]  

  • 9. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine.
    Krammer F; Srivastava K; Alshammary H; Amoako AA; Awawda MH; Beach KF; Bermúdez-González MC; Bielak DA; Carreño JM; Chernet RL; Eaker LQ; Ferreri ED; Floda DL; Gleason CR; Hamburger JZ; Jiang K; Kleiner G; Jurczyszak D; Matthews JC; Mendez WA; Nabeel I; Mulder LCF; Raskin AJ; Russo KT; Salimbangon AT; Saksena M; Shin AS; Singh G; Sominsky LA; Stadlbauer D; Wajnberg A; Simon V
    N Engl J Med; 2021 Apr; 384(14):1372-1374. PubMed ID: 33691060
    [No Abstract]   [Full Text] [Related]  

  • 10. Serological response in health care workers after a single dose of SARS-CoV-2 vaccine using six automated SARS-CoV-2 antibody assays.
    Cuykx M; Mortelé O; Jansens H; Schouwers S; Meskal A; Hoffbauer I; Peeters B
    Diagn Microbiol Infect Dis; 2021 Oct; 101(2):115486. PubMed ID: 34332306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients.
    Boyarsky BJ; Werbel WA; Avery RK; Tobian AAR; Massie AB; Segev DL; Garonzik-Wang JM
    JAMA; 2021 May; 325(17):1784-1786. PubMed ID: 33720292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.
    Schrezenmeier E; Bergfeld L; Hillus D; Lippert JD; Weber U; Tober-Lau P; Landgraf I; Schwarz T; Kappert K; Stefanski AL; Sattler A; Kotsch K; Dörner T; Sander LE; Budde K; Halleck F; Kurth F; Corman VM; Choi M
    Front Immunol; 2021; 12():690698. PubMed ID: 34276681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2).
    Favresse J; Bayart JL; Mullier F; Dogné JM; Closset M; Douxfils J
    Clin Microbiol Infect; 2021 Sep; 27(9):1351.e5-1351.e7. PubMed ID: 33975007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Immunogenicity of Anti-SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants.
    Marion O; Del Bello A; Abravanel F; Couat C; Faguer S; Esposito L; Hebral AL; Izopet J; Kamar N
    Ann Intern Med; 2021 Sep; 174(9):1336-1338. PubMed ID: 34029487
    [No Abstract]   [Full Text] [Related]  

  • 15. Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies.
    Wong SY; Dixon R; Martinez Pazos V; Gnjatic S; Colombel JF; Cadwell K;
    Gastroenterology; 2021 Aug; 161(2):715-718.e4. PubMed ID: 33887219
    [No Abstract]   [Full Text] [Related]  

  • 16. Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases.
    Thuluvath PJ; Robarts P; Chauhan M
    J Hepatol; 2021 Dec; 75(6):1434-1439. PubMed ID: 34454993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series.
    Werbel WA; Boyarsky BJ; Ou MT; Massie AB; Tobian AAR; Garonzik-Wang JM; Segev DL
    Ann Intern Med; 2021 Sep; 174(9):1330-1332. PubMed ID: 34125572
    [No Abstract]   [Full Text] [Related]  

  • 18. SARS-CoV-2 and the rheumatology patient: the last 12 months and a boost in the future.
    Winthrop KL; Whitley RJ; Aletaha D
    Ann Rheum Dis; 2021 Oct; 80(10):1249-1251. PubMed ID: 34518198
    [No Abstract]   [Full Text] [Related]  

  • 19. Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies.
    Ghione P; Gu JJ; Attwood K; Torka P; Goel S; Sundaram S; Mavis C; Johnson M; Thomas R; McWhite K; Darrall A; DeMarco J; Kostrewa J; Mohr A; Rivas L; Neiders M; Suresh L; Segal BH; Griffiths EA; Ramsperger V; Shen L; Hernandez-Ilizaliturri FJ
    Blood; 2021 Sep; 138(9):811-814. PubMed ID: 34189565
    [No Abstract]   [Full Text] [Related]  

  • 20. Neutralizing SARS-CoV-2.
    Poeschla E
    Elife; 2020 Dec; 9():. PubMed ID: 33320086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.